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Abstract
Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by difficulties in communication,
cognitive and learning deficits, as well as stereotypic behaviors. For the majority of cases there are no reliable
biomarkers or distinct pathogenesis. However, increasing evidence indicates ASD may be associated with some
immune dysregulation, and may have a neuroimmune component. We recently showed that the peptide neuro-
tensin (NT) is increased in autistic children. We now show that NT induces release of extracellular mitochondrial
DNA (mtDNA) that could act as “autoimmune” trigger. We further show that serum from young autistic patients
contains mtDNA (n = 20; cytochrome B, p = 0.0002 and 7S, p = 0.006), and anti-mitochondrial antibody Type 2
(n = 14; p = 0.001) as compared to normally developing, unrelated controls (n = 12). Extracellular blood mtDNA
and other components may characterize an autistic endophenotype and may contribute to its pathogenesis by
activating autoimmune responses.
Background
Autism spectrum disorders (ASD) are neurodevelopmen-
tal disorders characterized by varying degrees of dysfunc-
tional communication and social abilities, repetitive and
stereotypic behaviors, as well as attention, cognitive,
learning and sensory deficits [1]. The prevalence of ASD
has increased impressively during the last two decades
with the most current estimates being about 1/100
children [2]. In spite of numerous clues regarding the
possible underlying pathophysiology, there is major
disagreement among scholars as to the significance
of such clues for either the pathogenesis or diagnosis of
autism [1]. Moreover, there are no reliable biomarkers or
effective treatment of the core symptoms [3,4].
A number of papers have suggested that ASD may be
associated with some immune dysfunction in the patients
[5], or the mother during gestation [6,7]. However, these
papers do not provide support of direct relationship.
Additional evidence suggests that ASD may have a neu-
roimmune component [8]. In particular, it was recently
shown that the peptide neurotensin (NT) is significantly
increased in young children with autistic disorder [9]. A
number of studies reporting mitochondrial (mt) dysfunc-
tion in autism have focused on altered energy metabo-
lism [10], and concluded that it may involve a subset of
children with autism [11]. Mitochondria are the primary
energy-generating organelles in eukaryotic cells, and they
participate in multiple intracellular processes, including
calcium buffering [12]. However, mitochondria evolved
from bacteria that became symbiotic with eukaryotic
cells and are typically prevented from being released
extracellularly by autophagy [13].
We hypothesized that mitochondrial components,
such as mtDNA may be released extracellularly early in
life and induce an “autoimmune” response that may
contribute to the pathogenesis of autism.
Methods
Patients
We investigated a homogeneous group of young Cauca-
sian children with the same endophenotype. Subjects
were diagnosed with autistic disorder using the ADI-R
and ADOS-G scales, which have been validated in the
Greek population [14]. There were no apparent clinical
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differences, such as gastrointestinal problems, as
reported by the parents, or mitochondrial dysfunction,
as indirectly suggested by normal plasma lactate/pyru-
vate ratio, that may have allowed separation of the autis-
tic patients in subgroups.
Blood was obtained in the morning at least 2 hours
after breakfast to minimize any diurnal or postprandial
effects. Serum from patients and controls was aliquoted
and frozen at -80°C until assayed. All samples were
labeled only with a code number, as well as the age and
sex of the respective subject. Patients were recruited
from the Second Department of Psychiatry at Attikon
General Hospital, University of Athens Medical School
(Athens, Greece), an NIH-approved site for biological
samples. Parents signed an appropriate consent form
according to the Helsinki Principles. All children met
ICD-10 criteria for autistic disorder. The exclusion cri-
teria included: (1) any medical condition likely to be
etiological for ASD (e.g. Rett syndrome, focal epilepsy,
fragile X syndrome or tuberous sclerosis); (2) any neuro-
logic disorder involving pathology above the brain stem,
other than uncomplicated non-focal epilepsy; (3) con-
temporaneous evidence, or unequivocal retrospective
evidence, of probable neonatal brain damage; (4) any
genetic syndrome involving the CNS, even if the link
with autism is uncertain; (5) clinically significant visual
or auditory impairment, even after correction; (6) any
circumstances that might possibly account for the pic-
ture of autism (e.g. severe nutritional or psychological
deprivation); (7) active treatment with pharmacological
or other agents; (8) mastocytosis (including urticaria
pigmentosa); (9) history of upper airway diseases; (10)
history of inflammatory diseases; and (11) history of
allergies. The controls were normally developing, healthy
children, unrelated to the autistic subjects, and were
seen for routine health visits at the Pediatric Depart-
ment of the Institute of Social Health Insurance, Thessa-
loniki, Greece. There were no identifiers except for age
and sex. All autistic and control samples were collected
over a period of six months by trained health providers.
Serum was prepared immediately and stored in -80°C.
All autism and control samples were then transported
by the senior author on dry ice to Boston for analysis.
Previous work has shown that samples are stable at this
temperature. Moreover, DNA is known to be fairly
stable and can be stored for months even at -20°C.
Serum mtDNA and anti-mt antibody assays
Anti-mt antibody Type 2 (AMA-M2) was detected using a
commercial EIA Kit (DRG International, Germany) [15].
Total DNA was extracted from serum samples using Qia-
gen DNA Micro extraction kit (Qiagen, CA). Mitochon-
drial specific DNA for Cytochrome B (mt-CytB) and 7S
(mt-7S) was detected and quantified by Real time PCR
using Taqman assay (Mt-7S: Hs02596861_s1; Mt-CYB:
Hs02596867_s1; GAPDH: Hu, VIC, TAMRA, Applied Bio-
systems, CA) [16]. GAPDH DNA was used to exclude any
genomic “contamination” [16]. Total DNA was isolated
from supernatant fluids of cultured LAD2 cells using the
same method.
Culture of LAD2 mast cells
LAD2 cells (NIH, Bethesda, MD, USA) were cultured in
StemPro-34 SFM Medium (Invitrogen, Carlsbad, CA) sup-
plemented with 100 ng/ml recombinant human stem cell
factor (rhSCF, from Biovitrum, Sweden) and 1% U/ml
penicillin/streptomycin. Cells were grown in an incubator
in 5% CO2 and air environment at 37°C. All cells were
used during their logarithmic growth period.
Statistical analysis
Samples were thawed by Dr. Angelidou. The actual
qPCR and ELISA were conducted by Dr. Zhang. Data
analysis was done separately by both Dr. Zhang and
Dr. Angelidou under the supervision of Dr. Theoharides.
The results are presented as scattergrams, with the hori-
zontal lines indicating the means. The ASD group was
compared to the control using unpaired, unequal,
2-tailed, Student’s t-test, as well as the non-parametric
Mann-Whitney U test. Any correlation between inde-
pendent variables (mt-CytB DNA and mt-7S DNA, as
well as mt-CytB DNA and AMA-M2 protein amount)
was investigated using linear regression analysis. Signifi-
cance of comparisons between healthy subjects and sub-
jects with ASD is denoted by p < 0.05.
Results
We tested serum samples from autistic patients for
mtDNA (n = 20; 16 males and 4 females; mean age 3.0 ±
0.4 years) and AMA-M2 antibodies (n = 14; 11 males and
3 females; mean age 3.0 ± 0.4 years) compared to controls
(n = 12; 11 males and 1 female; mean age 3 ± 1.2 years).
The number of patients analyzed for AMA-M2 was smal-
ler only because of the lack of availability of the EIA kit
that would have allowed us to assay the rest of the patients.
We show that serum from young autistic children
contains amount of mtDNA significantly higher for mt-
CytB (p = 0.0002) and for mt-7S (p = 0.006) (Figure 1A
and 2B). Linear regression shows an excellent correla-
tion (R^2 = 0.89) between mt-CytB and 7S (Figure 1C.
No presence of GAPDH DNA was detected indicating
there was no genomic DNA release.
Serum of autistic patients also contains AMA-M2
antibodies (p = 0.001) compared to unrelated, normal
controls (Figure 2). However, there was no correlation
between mt-CytB DNA and AMA-M2 level (Figure 2B).
It is obvious from the scattergrams that the values
corresponding to the autistic patients seem to segregate
in 2 groups, indicating the possible presence of different
endophenotypes. However, nothing in the clinical
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presentation of these children allowed for obvious
separation of the subjects in subgroups.
We further hypothesized that NT may be able to trig-
ger release of extracellular mt components from human
mast cells. Stimulation of human cultured LAD2 cells
with NT (1, 5 and 10 μM, for 1 h at 37°C) resulted in
significant release of CytB and 7S mtDNA in the super-
natant fluid (Figure 3).
Discussion
Here we report the presence of serum extracellular
mtDNA and AMA-M2 in young children with autism.
Serum mtDNA have never been associated with any
neuropsychiatric disease. Moreover, AMA-M2 has been
clinically detected only in primary biliary cirrhosis [15].
Consequently, our findings are unique even though
there are no available data as to what serum levels of
either mtDNA or AMA-M2 may constitute an index of
a pathological process. However, mitochondria evolved
from bacteria that became symbiotic with eukaryotic
cells and are typically prevented from being released
extracellularly by autophagy [13]. Consequently, mtDNA
released extracellularly would be extremely immuno-
genic. It was recently reported that damage-associated
Figure 1 Serum levels of (A) mt DNA Cytochrome B (CytB) and (B) mt DNA 7S in autistic patients (n = 20; 11 males and 3 females;
mean age 3.0 ± 0.4 years) and controls (n = 12; 11 males and 1 female; mean age 3 ± 1.2 years). Genomic DNA GAPDH was
undetectable, excluding the possibility of cell contamination. The horizontal lines indicate the means.(C) Linear regression analysis showing
strong correlation between CytB and 7S.
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mitochondrial patterns (DAMPs), which contain
mtDNA, are present in the blood of patients with
trauma-induced sepsis in the absence of any apparent
infection and are able to activate toll-like receptor 9
(TLR9) on human peripheral polymorphonuclear leuko-
cytes leading to release of IL-8 [16].
The presence of extacellular mtDNA in children with
autism suggests that it may be one source of “autoimmune”
triggers, and may potentially explain some aspects of
immune dysregulation reported in autistic patients. For
instance, mtDNA (or other extracellular mitochondrial
components not measured in this study) could activate
TLRs on immune or glial cells to release pro-inflammatory
cytokines, such as IL-6, IL-8 or TNF, high gene expression
of which was reported in brains of autistic children [17].
Our present results do not imply any mitochondrial
dysfunction. Moreover, we cannot definitely state that
subjects didn't have any mitochondrial dysfunction,
since such confirmation requires extensive clinical and
laboratory evaluation [18,19] that was not performed in
this case. Mitochondrial dysfunction has been reported
in a subset of children with autism [11,20], but appar-
ently is not linked to altered energy metabolism [10].
Such subsets of ASD children with mitochondrial dys-
function may be more vulnerable to regression following
a febrile episode [21].
The source of the extracellular mtDNA and other
mitochondrial components in the serum of autistic
patients is not presently known. There is no reason to
suspect that these derive from apoptotic or necrotic cells
because no GAPDH DNA was detected. Moreover, there
is no apparent cell damage, at least outside the brain, in
autism. One possibility is that mt components are
secreted from immune cells, as was recently reported for
activated neutrophils [22]. Another possibility could be
activated tissue mast cells in the gut, where NT [23]is
abundant and may induce mucosal permeability [24].
Our current findings showing that NT can trigger
mtDNA release from human mast cells is supported by
our previous report that NT, found both in the brain and
the gut was elevated in autistic children [9].
The present results may be limited only to autistic disor-
der and only to the young age of the subjects studied.
Nevertheless, these results suggest that serum mt compo-
nents may induce autoimmune responses, as previously
reported for TLR9 activation on human peripheral
Figure 2 Serum levels of anti-mt antibodies type 2 (AMA-M2) in autistic children (n = 14; 11 males and 3 females; mean age 3.0 ± 0.4
years) and controls (n = 12; 11 males and 1 female; mean age 3 ± 1.2 years). The horizontal lines indicate the means. AMA-M2 level were
measured in International Unit (IU)/ml. (B) Linear regression analysis showing no correlation between mtDNA and AMA-M2.
Figure 3 Mitochondrial DNA detected in the supernatant fluid
from NT-stimulated LAD2 cells. LAD2 cells were stimulated with
NT (1, 5, 10 μM) for 1 hr. Mitochondrial specific DNA mt-7S and mt-
CytB were detected and quantified by Real time PCR using Taqman
assay (Applied Biosystems, CA). Genomic DNA GAPDH was
undetectable, excluding the possibility of cell contamination
(*p < 0.01, **p < 0.0001).
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polymorphonuclear leukocytes [16], and may help with
early diagnosis of at least a subgroup of autistic patients.
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